Welcome to our dedicated page for Oncternal Therapeutics news (Ticker: ONCT), a resource for investors and traders seeking the latest updates and insights on Oncternal Therapeutics stock.
Oncternal Therapeutics Inc (ONCT) is a clinical-stage biopharmaceutical company advancing novel therapies for hematological malignancies and prostate cancer. This page aggregates official press releases and verified news about their innovative pipeline, including ROR1-targeted CAR T cell therapies and dual-action androgen receptor inhibitors.
Investors and researchers will find timely updates on clinical trial progress, regulatory milestones, and strategic partnerships. The curated collection includes announcements about trial initiations, scientific presentations, manufacturing developments, and collaborative research efforts in precision oncology.
All content is sourced directly from company filings and authorized publications, ensuring reliability for investment decision-making. Bookmark this page for streamlined access to ONCT's latest advancements in developing treatments for cancers with significant unmet needs.
Oncternal Therapeutics, Inc. (Nasdaq: ONCT) has appointed Chase Leavitt as General Counsel, effective April 12, 2021. Leavitt brings extensive legal experience from leading biotech and technology firms, which is expected to bolster Oncternal's growth trajectory.
Leavitt's responsibilities will include navigating legal compliance and governance as the company develops its ROR1-targeting therapies and other oncology products. He received a B.S. and J.D. from the University of Southern California, adding valuable expertise to Oncternal's leadership team.
Oncternal Therapeutics, Inc. (Nasdaq: ONCT) announced promising interim results from a Phase 1b trial of cirmtuzumab combined with paclitaxel in HER2-negative breast cancer, showing a 57% partial response rate among evaluable patients. In preclinical studies, cirmtuzumab demonstrated single-agent efficacy and enhanced effects with standard chemotherapies against high-grade serous ovarian and endometrial cancers. Additionally, investigational selective androgen receptor degraders showed inhibition of tumor growth in androgen receptor-positive triple-negative breast cancer models. The company continues to advance its clinical programs.
Oncternal Therapeutics, Inc. (Nasdaq: ONCT) announced the granting of an inducement award to new Senior VP of Human Resources, Anita Wiseth, on March 18, 2021. The award includes options for 90,000 shares at an exercise price of $8.36, vesting over four years. This grant, part of Oncternal’s 2021 Employment Inducement Incentive Award Plan, was approved by an independent compensation committee in compliance with Nasdaq regulations. The company focuses on developing novel oncology therapies targeting significant unmet medical needs.
Oncternal Therapeutics (Nasdaq: ONCT) reported encouraging interim results for cirmtuzumab combined with ibrutinib in its ongoing Phase 1/2 study for mantle cell lymphoma (MCL), showing a 47% complete response (CR) rate versus a historical 20% CR. The company is advancing ROR1-targeting CAR-T therapies and has two durable responses reported in Ewing sarcoma patients treated with TK216. Financially, Oncternal raised $125 million in 2020 to support its pipeline, with a net loss of $17.2 million for the year and $116.7 million cash on hand as of December 31, 2020.
Oncternal Therapeutics, Inc. (Nasdaq: ONCT) will report its fourth quarter and full year 2020 financial results on March 11, 2021, post-market. A webcast will follow at 2:00 p.m. PT for management to discuss the results and provide a business update. Oncternal is focused on developing novel oncology therapies addressing unmet medical needs, with ongoing clinical studies for cirmtuzumab and TK216. The company's primary aim is to tap into promising biological pathways involved in cancer progression.
Oncternal Therapeutics (Nasdaq: ONCT) will participate in two significant virtual conferences in March 2021. The first is the H.C. Wainwright Global Life Sciences Conference on March 9, starting at 7:00 AM ET, with James Breitmeyer presenting. The second event is the Oppenheimer 31st Annual Healthcare Conference on March 16, at 4:30 PM ET, also featuring Breitmeyer. Both presentations will be available for streaming, and links can be found on Oncternal's investor website. The company focuses on developing innovative oncology therapies.
Oncternal Therapeutics, Inc. (Nasdaq: ONCT) announced the granting of an inducement award to Christy Stolzer, its new Associate Director of Drug Safety, on February 22, 2021. The award includes options to purchase 60,000 shares of common stock at an exercise price of $7.20 per share, vesting over four years. This grant adheres to Oncternal's 2021 Employment Inducement Incentive Award Plan, aimed at attracting new employees. The options were approved by the independent compensation committee as required by Nasdaq regulations.
Oncternal Therapeutics appointed Dr. Rosemary Mazanet to its Board of Directors, effective January 27, 2021. She brings extensive oncology drug development experience, having led initiatives at Amgen and serving in leadership roles in various biopharma companies. Dr. Mazanet's expertise is expected to enhance Oncternal's ongoing projects, including cirmtuzumab and ROR1 CAR-T programs. Oncternal focuses on innovative oncology therapies targeting unmet medical needs, with clinical trials underway for its candidates.
Oncternal Therapeutics, Inc. (Nasdaq: ONCT) announced a partnership with Lentigen Technology to manufacture lentiviral vectors for its ROR1-targeting CAR-T cell therapy program. The agreement aims to accelerate the development of this innovative cancer treatment, with GMP manufacturing reserved for 2021. Oncternal's President noted the significance of ROR1 as a target in oncology, with plans to achieve first-in-human dosing in the latter half of 2021. This collaboration underscores Oncternal's commitment to advancing cancer therapies with high unmet medical needs.
Oncternal Therapeutics (Nasdaq: ONCT) announced a collaboration with Karolinska Institutet in Sweden to develop ROR1-targeting cell therapies, enhancing their CAR-T and CAR-NK programs. This partnership includes IND-supporting preclinical studies led by Evren Alici, M.D., in the NextGenNK Center. The collaboration aims to leverage Oncternal's cirmtuzumab in developing novel cancer treatment options for hematologic and solid tumors. ROR1 is recognized as a promising target for these therapies, potentially leading to improved efficacy and safety in patient treatments.
